Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- A systematic review and meta-regression of temporal trends in the excess mortality associated with diabetes mellitus after myocardial infarction.Int J Cardiol. 2016; 217: 109-121
- A decade of changes in clinical characteristics and management of elderly patients with non-ST-elevation myocardial infarction admitted in Italian cardiac care units.Open Heart. 2014; 1e000148
De Luca L, Marini M, Gonzini L, et al. Contemporary trends and age-specific sex differences in management and outcome for patients with ST-segment elevation myocardial infarction. J Am Heart Assoc. 2016;5(12). pii: e004202
- Temporal trends in the epidemiology, management and outcome of patients with cardiogenic shock complicating acute coronary syndromes.Eur J Heart Fail. 2015; 17: 1124-1132
- Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation.Int J Cardiol. 2017; 248: 369-375
- Trends in management and outcome of patients with non-ST elevation acute coronary syndromes and peripheral arterial disease.Eur J Intern Med. 2019; 59: 70-76
- et al; BLITZ Investigators. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study.Eur Heart J. 2003; 24: 1616-1629
- et al; IN-ACS Outcome Investigators. Clinical epidemiology, management and outcome of acute coronary syndromes in the Italian network on acute coronary syndromes (IN-ACS Outcome study).Acute Card Care. 2012; 14: 71-80
- Management of patients with acute coronary syndromes in real-world practice in Italy: an outcome research study focused on the use of ANTithRombotic Agents: the MANTRA registry.Eur Heart J Acute Cardiovasc Care. 2013; 2: 27-34
- The management of acute myocardial infarction in the cardiological intensive care units in Italy: the 'BLITZ 4 Qualità' campaign for performance measurement and quality improvement.Eur Heart J Acute Cardiovasc Care. 2012; 1: 143-152
- Cavallini C, et al.EYESHOT Investigators Contemporary antithrombotic strategies in patients with acute coronary syndromes admitted to cardiac care units in Italy: the EYESHOT study Eur Heart J Acute Cardiovasc Care. 2015; 4: 441-452
- Assessing kidney function--measured and estimated glomerular filtration rate.N Engl J Med. 2006; 354: 2473-2483
- Diabetes and mortality following acute coronary syndromes.JAMA. 2007; 298: 765-775
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD–summary.Eur Heart J. 2013; 34: 3035-3087
- et al; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants.Lancet. 2011; 378: 31-40
- Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005.Circulation. 2009; 119: 1728-1735
- et al; on behalf of the CULPRIT-SHOCK Investigators. Multivessel PCI in cardiogenic shock complicating acute myocardial infarction.N Engl J Med. 2017; 377: 2419-2432
- Heart failure: the frequent, forgotten, and often fatal complication of diabetes.Diabetes Care. 2003; 26: 2433-2441
- Diabetic cardiomyopathy revisited.Circulation. 2007; 115: 3213-3223
- Predictors of mortality in hospital survivors with type-two diabetes mellitus and acute coronary syndromes.Diab Vasc Dis Res. 2018; 15: 14-23
- Effect of a multifactorial intervention on mortality in type 2 diabetes.N Engl J Med. 2008; 358: 580-591
- Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.Lancet Diabetes Endocrinol. 2017; 5: 391-402
Funding: The studies included in this manuscript were funded by unrestricted grants, as follows: BLITZ (Boehringer Ingelheim, Italy), IN-ACS Outcome (Sanofi-Aventis and Bristol-Myers Squibb, Italy), BLITZ 4 (Merck, Sharp&Dohme, Italy), MANTRA (GlaxoSmithKline, Italy) and EYESHOT (AstraZeneca, Italy). The sponsor of the studies was the Heart Care Foundation, a nonprofit independent institution that is also the owner of the databases. Database management and quality control of the data were under the responsibility of the Research Centre of the Italian Association of Hospital Cardiologists (ANMCO). The Steering Committees of the studies had full access to all the data in the studies and took complete responsibility for the integrity of the data and the accuracy of data analysis.
Conflict of Interest: None.
Authorship: All authors had access to the data and a role in writing this manuscript. MD, NM, and SS prepared the first draft of the manuscript. LG and DL did the statistical analysis. ADC, AB, ZO, GC, and LDL chaired the individual Intensive Cardiac Care Unit registries that were the basis for the present analysis and revised the final manuscript. PT, SDS, and EB reviewed the results and provided substantial intellectual support to the discussion. SS wrote the final version of the manuscript.